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enzyme Oncogenic alteration functional outcome
PFKFB3 The PFK2 isoform PFKFB3 is highly expressed in several human 
cancers, including colon, prostate, breast, ovary, and thyroid. 
Most PFK2 isoforms both generate and degrade F-2,6-bisP, which activates PFK1 to increase fl ux through glyco-
lysis. PFKFB3 has no phosphatase activity and its kinase activity may be stimulated by several oncogenic events, 
further promoting glycolytic fl ux.
PHGDH Genomic regions containing the PHGDH gene are amplifi ed in 
breast cancer and melanoma. 
PHGDH overexpression not only increases serine synthetic pathway fl ux to sustain cell proliferation but also 
generates αKG.
PGAM1 PGAM1 is upregulated in colorectal cancer and hepatocellular 
carcinoma, likely due to TP53 loss.
PGAM1 balances intracellular 3-phosphoglycerate and 2-phosphoglycerate levels, which regulate oxidative pentose 
phosphate pathway and serine synthetic pathway activities, respectively. 
PKM2 Many cancer cells express the M2 isoform of PK. Tyrosine kinase 
signaling, including phosphorylation at Y105, reduces enzyme 
activity.
Low PKM2 catalytic activity causes accumulation of upstream glycolytic intermediates, promoting diversion of 
3-phosphoglycerate into the serine synthetic pathway.
FAS Highly expressed in human cancer, FAS expression is associated 
with poor prognosis in breast and prostate cancer.
While precise functional consequences have not been elucidated, FAS catalyzes fatty acid synthesis to support de 
novo lipogenesis and is critical for cell growth. 
IDH1 Somatic missense mutations at R132 are prevalent in glioma, 
acute myeloid leukemia, and other cancers and confer neomor-
phic enzyme activity converting αKG to 2HG.
2HG can act as a competitive antagonist of multiple αKG-dependent dioxygenase enzymes, including DNA 
5-methylcytosine hydroxylase TET2 and Jumonji C histone demethylase enzymes. Increased DNA and histone 
methylation may be linked to impaired cell differentiation.
IDH2 Missense mutations at R172 (the analogous residue to IDH1 R132) 
as well as the non-analogous residue R140 can lead to elevated 
2HG levels.
IDH2 mutations can recapitulate many of the effects of IDH1 mutations. However, IDH1 and IDH2 mutations are 
found with distinct frequencies across different cancers, suggestive of subtle biochemical differences. 
SDH Germline loss-of-function mutations in any of the four subunits of 
SDH or the SDH assembly factor are associated with hereditary 
forms of pheochromocytoma and/or paraganglioma.
Succinate can competitively inhibit multiple αKG dependent dioxygenases, including the prolyl hydroxylases that 
promote HIFα degradation. Elevated HIFα may provide a growth advantage under particular conditions.
FH Hereditary mutations can underlie cutaneous and uterine leiomyo-
mas and renal cell cancer. 
The pathogenic mechanisms are unclear. Fumarate may inhibit αKG-dependent dioxygenases and stabilize HIFα. 
Fumarate can also directly modify a cysteine residue on KEAP1, increasing antioxidant response genes that may 
promote cancer cell survival.
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Proliferating cells rewire their metabolism to support growth. Quiescent cells break down fuels such as glucose, glutamine, and fatty acids for complete oxidation to carbon 
dioxide through the tricarboxylic acid cycle (TCA cycle). The chemical energy of these fuels is harnessed by reducing electron carriers NAD+ and FAD to NADH and FADH2, 
respectively. These high-energy electrons are used to generate large amounts of adenosine triphosphate (ATP) by the mitochondrial electron transport chain. In this manner, 
quiescent cells efficiently convert nutrients into energy to sustain basic cellular processes. In contrast, rapidly proliferating cells must generate the proteins, lipids, and nucleic 
acids necessary to create a daughter cell. Consequently, cells take up large amounts of nutrients such as glucose and glutamine that are used to support cell growth. Intermedi-
ates of glycolysis and the TCA cycle provide the building blocks for nucleic acids, amino acids, and fatty acids. Glutamine catabolism maintains a steady supply of nutrients into 
the TCA cycle (anaplerosis), thus preserving the TCA cycle integrity despite continual efflux of metabolites to support growth.
Anabolic Cell Growth
In order to grow and divide, cells must be able to synthesize nucleotides, proteins, and lipids from exogenous glucose, glutamine, and essential amino acids. The signaling path-
ways controlling nutrient uptake (shown in orange) are frequently activated in cancer and directly fuel anabolic pathways. In particular, the PI3K/Akt pathway regulates the import 
and retention of glucose, thus providing substrates for glycolysis and the biosynthetic pathways that rely on continual supply of glycolytic intermediates. mTOR, downstream of 
Akt signaling, regulates the rate of protein translation, fueled by the supply of charged tRNAs generated by amino acid uptake and biosynthesis. Similarly, MYC regulates several 
steps in glutamine uptake and catabolism, ensuring a steady supply of nitrogen for nucleotide biosynthesis and α-ketoglutarate to fuel the TCA cycle. In turn, intermediates of 
glycolysis and the TCA cycle are used to generate the three major macromolecules required for growth. Glycolytic intermediates can be metabolized through the pentose phos-
phate pathway to generate the ribose-5-phosphate that represents the critical sugar backbone for nucleic acids. The glycolytic intermediate 3-phosphoglycerate is metabolized 
by PHGDH to produce serine and glycine, which in turn can contribute to pools of nonessential amino acids to fuel protein synthesis. Serine and glycine metabolism can also 
contribute to the pool of one-carbon metabolites that support nucleotide biosynthesis. Citrate, generated by the TCA cycle and exported to the cytoplasm, provides the critical 
acetyl-CoA building blocks for fatty acid synthesis.
A large number of metabolic enzymes (highlighted in blue) are amplified, alternatively spliced, or mutated in the pathogenesis of cancer (see table). These include alterations 
that increase flux through glycolysis (PFKFB3, PGAM1) or diversion of glycolytic intermediates to biosynthetic pathways (PHGDH). Tyrosine kinase signaling downstream of 
oncogenic events serves to inhibit PKM2, thereby decreasing the rate of terminal glycolysis and increasing the availability of upstream metabolites for biosynthetic pathways. 
High FAS expression promotes the synthesis of fatty acids that are required for lipid biogenesis. Mutations that impair the function of SDH and FH trigger accumulation of abnor-
mal levels of succinate and fumarate, respectively. While wild-type IDH enzymes catalyze the oxidative decarboxylation of isocitrate to produce αKG, gain-of-function mutations 
in the two NADP+-dependent IDH enzymes, mitochondrial IDH2 and cytosolic IDH1, enable the enzymes to reduce αKG, forming high levels of 2-hydroxyglutarate. All three of 
these pathologically accumulated metabolites (blue ovals) can impair the ability of cells to carry out α-ketoglutarate-dependent processes, with implications for cell survival and 
differentiation. Together, these findings demonstrate that oncogenic events influence the pathways of nutrient uptake and critical nodes of metabolism in order to support ana-
bolic growth. Common oncogenic events are shown in orange. Metabolites and metabolic enzymes whose level, expression, or activity is altered in cancer are shown in blue.
Abbreviations
2HG, 2-hydroxyglutarate; αKG, α-ketoglutarate; ACL, ATP-citrate lyase; ATP, adenosine triphosphate; F-2,6-bisP, fructose 2,6-bisphosphate; FAS, fatty acid synthase; FH, 
fumarate hydratase; *GLDC, glycine decarboxylase. Note that this reaction occurs in the mitochondrion; HIFα, hypoxia-inducible factor, alpha subunit; HKII, hexokinase 2; IDH1, 
isocitate dehydrogenase 1; IDH2, isocitrate dehydrogenase 2; LDHA, lactate dehydrogenase A; mTOR, mechanistic target of rapamycin; PFKFB3, phosphofructo-2-kinase/
fructose-2,6-bisphosphatase 3; PGAM1, phosphoglycerate mutase 1; PHGDH, phosphoglycerate dehydrogenase; PI3K, phosphoinositide 3-kinase; PKM2, pyruvate kinase M2; 
RTK, receptor tyrosine kinase; SDH, succinate dehydrogenase; THF, tetrahydrofolate; Tyr-K, tyrosine kinase.
RefeRences
DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 
11–20.
Lunt, S.Y., and Vander Heiden, M.G. (2011). Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441–464.
Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033.
Wallace, D.C. (2012). Mitochondria and cancer. Nat. Rev. Cancer 12, 685–698.
Ward, P.S., and Thompson, C.B. (2012). Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21, 297–308.
466.e2 Cell Met. 17-3, March 5, 2013 ©2013 Elsevier Inc. DOI http://dx.doi.org/10.1016/j.cmet.2013.02.016 
SnapShot: Cancer Metabolism 
Pathways
Lydia W. S. Finley, Ji Zhang, Jiangbin Ye, Patrick S. Ward, and Craig B. Thompson
Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
Further Reading
Adam, J., Hatipoglu, E., O’Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G.W., Wolhuter, K., et al. (2011). Renal cyst formation in Fh1-deficient mice is independent of the 
Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20, 524–537.
Amary, M.F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O’Donnell, P., Grigoriadis, A., Diss, T., et al. (2011). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma 
and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 224, 334–343.
Atsumi, T., Chesney, J., Metz, C., Leng, L., Donnelly, S., Makita, Z., Mitchell, R., and Bucala, R. (2002). High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; 
PFKFB3) in human cancers. Cancer Res. 62, 5881–5887.
Bando, H., Atsumi, T., Nishio, T., Niwa, H., Mishima, S., Shimizu, C., Yoshioka, N., Bucala, R., and Koike, T. (2005). Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 
family of glycolytic regulators in human cancer. Clin. Cancer Res. 11, 5784–5792.
Bardella, C., Pollard, P.J., and Tomlinson, I. (2011). SDH mutations in cancer. Biochim. Biophys. Acta 1807, 1432–1443.
Boissel, N., Nibourel, O., Renneville, A., Huchette, P., Dombret, H., and Preudhomme, C. (2011). Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 
117, 3696–3697.
Borger, D.R., Tanabe, K.K., Fan, K.C., Lopez, H.U., Fantin, V.R., Straley, K.S., Schenkein, D.P., Hezel, A.F., Ancukiewicz, M., Liebman, H.M., et al. (2012). Frequent mutation of isocitrate dehydrogenase (IDH)1 
and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17, 72–79.
Chaneton, B., Hillmann, P., Zheng, L., Martin, A.C., Maddocks, O.D., Chokkathukalam, A., Coyle, J.E., Jankevics, A., Holding, F.P., Vousden, K.H., et al. (2012). Serine is a natural ligand and allosteric activa-
tor of pyruvate kinase M2. Nature 491, 458–462.
Christofk, H.R., Vander Heiden, M.G., Wu, N., Asara, J.M., and Cantley, L.C. (2008). Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181–186.
Clem, B., Telang, S., Clem, A., Yalcin, A., Meier, J., Simmons, A., Rasku, M.A., Arumugam, S., Dean, W.L., Eaton, J., et al. (2008). Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses 
glycolytic flux and tumor growth. Mol. Cancer Ther. 7, 110–120. 
Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., et al. (2010). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. 
Nature 465, 966.
Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation 
phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567.
Flavin, R., Peluso, S., Nguyen, P.L., and Loda, M. (2010). Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 6, 551–562.
Green, C.L., Evans, C.M., Zhao, L., Hills, R.K., Burnett, A.K., Linch, D.C., and Gale, R.E. (2011). The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118, 
409–412.
Gross, S., Cairns, R.A., Minden, M.D., Driggers, E.M., Bittinger, M.A., Jang, H.G., Sasaki, M., Jin, S., Schenkein, D.P., Su, S.M., et al. (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates 
in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339–344.
Hitosugi, T., Kang, S., Vander Heiden, M.G., Chung, T.W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G.Z., et al. (2009). Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect 
and tumor growth. Sci. Signal. 2, ra73.
Hitosugi, T., Zhou, L., Elf, S., Fan, J., Kang, H.B., Seo, J.H., Shan, C., Dai, Q., Zhang, L., Xie, J., et al. (2012). Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. 
Cancer Cell 22, 585–600.
Isaacs, J.S., Jung, Y.J., Mole, D.R., Lee, S., Torres-Cabala, C., Chung, Y.L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005). HIF overexpression correlates with biallelic loss of fumarate hydratase in 
renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143–153.
Kranendijk, M., Struys, E.A., van Schaftingen, E., Gibson, K.M., Kanhai, W.A., van der Knaap, M.S., Amiel, J., Buist, N.R., Das, A.M., de Klerk, J.B., et al. (2010). IDH2 mutations in patients with D-2-
hydroxyglutaric aciduria. Science 330, 336.
Locasale, J.W., Grassian, A.R., Melman, T., Lyssiotis, C.A., Mattaini, K.R., Bass, A.J., Heffron, G., Metallo, C.M., Muranen, T., Sharfi, H., et al. (2011). Phosphoglycerate dehydrogenase diverts glycolytic flux 
and contributes to oncogenesis. Nat. Genet. 43, 869–874.
Lu, C., Ward, P.S., Kapoor, G.S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C.R., Khanin, R., Figueroa, M.E., Melnick, A., et al. (2012). IDH mutation impairs histone demethylation and results in a 
block to cell differentiation. Nature 483, 474–478.
Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., et al. (2009). Recurring mutations found by sequencing an acute 
myeloid leukemia genome. N. Engl. J. Med. 361, 1058–1066.
Ooi, A., Wong, J.C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B.W., Tan, M.H., Zhang, Z., Yang, X.J., et al. (2011). An antioxidant response phenotype shared between hereditary and 
sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20, 511–523.
Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.M., Gallia, G.L., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Sci-
ence 321, 1807–1812.
Possemato, R., Marks, K.M., Shaul, Y.D., Pacold, M.E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.K., Jang, H.G., Jha, A.K., et al. (2011). Functional genomics reveal that the serine synthesis pathway 
is essential in breast cancer. Nature 476, 346–350.
Sasaki, M., Knobbe, C.B., Itsumi, M., Elia, A.J., Harris, I.S., Chio, I.I., Cairns, R.A., McCracken, S., Wakeham, A., Haight, J., et al. (2012). D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen 
maturation and basement membrane function. Genes Dev. 26, 2038–2049.
Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B., and Gottlieb, E. (2005). Succinate links TCA cycle dysfunction to oncogen-
esis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77–85.
Shah, U.S., Dhir, R., Gollin, S.M., Chandran, U.R., Lewis, D., Acquafondata, M., and Pflug, B.R. (2006). Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum. 
Pathol. 37, 401–409.
Tomlinson, I.P., Alam, N.A., Rowan, A.J., Barclay, E., Jaeger, E.E., Kelsell, D., Leigh, I., Gorman, P., Lamlum, H., Rahman, S., et al. (2002). Germline mutations in FH predispose to dominantly inherited uterine 
fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406–410.
Vander Heiden, M.G., Locasale, J.W., Swanson, K.D., Sharfi, H., Heffron, G.J., Amador-Noguez, D., Christofk, H.R., Wagner, G., Rabinowitz, J.D., Asara, J.M., et al. (2010). Evidence for an alternative glyco-
lytic pathway in rapidly proliferating cells. Science 329, 1492–1499.
Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., et al. (2010). The common feature of leukemia-associated IDH1 and IDH2 
mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234.
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang, P., Xiao, M.T., et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent 
dioxygenases. Cancer Cell 19, 17–30.
Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J., et al. (2009). IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 
765–773.
Ye, J., Mancuso, A., Tong, X., Ward, P.S., Fan, J., Rabinowitz, J.D., and Thompson, C.B. (2012). Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. 
Proc. Natl. Acad. Sci. USA 109, 6904–6909.
Zscharnack, K., Kessler, R., Bleichert, F., Warnke, J.P., and Eschrich, K. (2009). The PFKFB3 splice variant UBI2K4 is downregulated in high-grade astrocytomas and impedes the growth of U87 glioblas-
toma cells. Neuropathol. Appl. Neurobiol. 35, 566–578.
